Zymeworks Inc (ZYME) has released an update to notify the public and investors about its officers.
Zymeworks Inc. has announced the appointment of Dr. Alessandra Cesano to its board as a Class I director, with her term set to expire at the 2025 annual general meeting. Dr. Cesano, who has no conflicts of interest requiring disclosure, will be compensated according to the company’s standard plan for non-employee directors, including an initial stock option grant for 74,000 shares. Simultaneously, Dr. Kenneth Hillan’s resignation from the board has been confirmed, effective on the same date as Dr. Cesano’s appointment. Dr. Cesano will also take on Dr. Hillan’s former committee roles, while Mr. Derek Miller has been named the new chair of the nominating and corporate governance committee. The company’s compensation policy for non-employee directors includes both cash and equity, with specific amounts detailed for various roles and committees.
For further insights into ZYME corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.
